Dan Sherman

Title: Innovations by Dan Sherman in B-cell Lymphoma Treatment

Introduction

Dan Sherman is an accomplished inventor based in Madison, CT (US). He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target B-cell lymphoma. With a total of 2 patents to his name, Sherman is recognized for his innovative approaches to treating diseases associated with protein aggregation.

Latest Patents

Sherman's latest patents focus on modulators of BCL6 proteolysis and associated methods of use. These bifunctional compounds are designed to act as modulators of B-cell lymphoma 6 protein (BCL6), which is a critical target protein in the treatment of certain cancers. The compounds feature a unique design that includes a ligand binding to E3 ubiquitin ligases on one end and a moiety that binds the target protein on the other. This configuration allows for the effective degradation and inhibition of the target protein, showcasing a broad range of pharmacological activities. The compounds aim to treat or prevent diseases that result from the aggregation or accumulation of the target protein.

Career Highlights

Dan Sherman is currently associated with Arvinas Operations, Inc., where he continues to advance his research and development efforts. His work has been pivotal in creating innovative solutions for complex medical challenges.

Collaborations

Some of Sherman's notable coworkers include Michael Berlin and Hanqing Dong, who contribute to the collaborative environment that fosters innovation at Arvinas Operations, Inc.

Conclusion

Dan Sherman exemplifies the spirit of innovation in the biotechnology sector, particularly through his work on B-cell lymphoma treatments. His patents reflect a commitment to addressing significant health challenges through scientific advancement.